Rigosertib

Identification

Generic Name

Rigosertib

DrugBank Accession Number

DB12146

Background

Rigosertib has been used in trials studying the treatment and basic science of MDS, RAEB, Cancer, Hepatoma, and Neoplasms, among others.

Type

Small Molecule

Groups

Investigational

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Rigosertib (DB12146)

×

Close

Weight

Average: 451.49
Monoisotopic: 451.130087943

Chemical Formula

C₂₁H₂₅NO₈S

Synonyms

• Rigosertib

External IDs

• ON 01910
• ON-01910

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Ambroxol	The risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Ambroxol.
Articaine	The risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Articaine.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Benzocaine.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Benzyl alcohol.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Bupivacaine.
Butacaine	The risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Butamben.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Capsaicin.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Chloroprocaine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Cinchocaine.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

Not Available

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Rigosertib Sodium	406FL5G00V	592542-60-4	VLQLUZFVFXYXQE-USRGLUTNSA-M

Categories

Drug Categories

• Amino Acids
• Amino Acids, Peptides, and Proteins
• Antineoplastic Agents
• Enzyme Inhibitors
• Protein Kinase Inhibitors
• Sulfur Compounds

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as alpha amino acids. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon).

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Alpha amino acids

Alternative Parents

Aminophenyl ethers / Methoxyanilines / Anisoles / Styrenes / Methoxybenzenes / Phenoxy compounds / Phenylalkylamines / Alkyl aryl ethers / Secondary alkylarylamines / Sulfones / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Hydrocarbon derivatives / Organic oxides / Organopnictogen compounds / Carbonyl compounds

show 7 more

Substituents

Alkyl aryl ether / Alpha-amino acid / Amine / Amino acid / Aminophenyl ether / Aniline or substituted anilines / Anisole / Aromatic homomonocyclic compound / Benzenoid / Carbonyl group / Carboxylic acid / Ether / Hydrocarbon derivative / Methoxyaniline / Methoxybenzene / Monocarboxylic acid or derivatives / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Organosulfur compound / Phenol ether / Phenoxy compound / Phenylalkylamine / Secondary aliphatic/aromatic amine / Secondary amine / Styrene / Sulfone / Sulfonyl

show 22 more

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

Not Available

Affected organisms

Not Available

Chemical Identifiers

UNII

67DOW7F9GL

CAS number

592542-59-1

InChI Key

OWBFCJROIKNMGD-BQYQJAHWSA-N

InChI

InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+

IUPAC Name

2-[(2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenyl)amino]acetic acid

SMILES

COC1=CC(OC)=C(\C=C\S(=O)(=O)CC2=CC=C(OC)C(NCC(O)=O)=C2)C(OC)=C1

References

General References

Not Available

External Links

PubChem Compound

6918736

PubChem Substance

347828442

ChemSpider

5293927

BindingDB

50060917

ChEBI

145417

ChEMBL

CHEMBL1241855

ZINC

ZINC000003942646

PDBe Ligand

6FS

Wikipedia

Rigosertib

PDB Entries

5j18 / 5j2r / 5ov7

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
3	Completed	Treatment	Chronic Myelomonocytic Leukemia / Cytopenias / Myelodysplastic Syndrome / Refractory Anemia With Excess of Blasts (RAEB)	1
3	Completed	Treatment	Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Refractory Anemia With Excess of Blasts (RAEB)	1
3	Completed	Treatment	Pancreatic Adenocarcinoma Metastatic	1
3	Terminated	Treatment	Myelodysplastic Syndrome / Refractory Anemia With Excess of Blasts (RAEB)	1
2	Completed	Treatment	Acute Myeloid Leukemia / Leukemias / Myelodysplastic Syndrome	1
2	Completed	Treatment	Anal Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma / Cutaneous Squamous Cell Carcinoma / Esophageal Squamous Cell Carcinoma (ESCC) / Penile squamous cell carcinoma / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Squamous Cell Carcinoma of the Lung	1
2	Completed	Treatment	Myelodysplastic Syndrome	2
2	Completed	Treatment	Myelodysplastic Syndrome / Trisomy 8	1
2	Completed	Treatment	Ovarian Cancer	1
2	Recruiting	Treatment	Clinical Stage III Cutaneous Melanoma AJCC v8 / Clinical Stage IV Cutaneous Melanoma AJCC v8 / Metastatic Melanoma / Refractory Melanoma / Unresectable Melanoma	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0226 mg/mL	ALOGPS
logP	2.64	ALOGPS
logP	-0.25	Chemaxon
logS	-4.3	ALOGPS
pKa (Strongest Acidic)	2.27	Chemaxon
pKa (Strongest Basic)	5.24	Chemaxon
Physiological Charge	-1	Chemaxon
Hydrogen Acceptor Count	9	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	120.39 Å2	Chemaxon
Rotatable Bond Count	11	Chemaxon
Refractivity	116.5 m3·mol-1	Chemaxon
Polarizability	46.32 Å3	Chemaxon
Number of Rings	2	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at October 20, 2016 21:28 / Updated at February 21, 2021 18:53